Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (NCT06932263)
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
🩺 Plain-English Summary (8th-Grade Level)
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Who can join: Review the eligibility criteria below.
Location: Research Site — Bakersfield, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (221 Sites)
Showing the first 25 of 221 sites.
- Research Site — Bakersfield, California
- Research Site — Huntington Beach, California
- Research Site — La Mesa, California
- Research Site — Loma Linda, California
- Research Site — Long Beach, California
- Research Site — Newport Beach, California
- Research Site — San Jose, California
- Research Site — Wilmington, Delaware
- Research Site — Cutler Bay, Florida
- Research Site — Hialeah, Florida
- Research Site — Leesburg, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Miami Lakes, Florida
- Research Site — Orlando, Florida
- Research Site — Palmetto Bay, Florida
- Research Site — Tampa, Florida
- Research Site — Winter Park, Florida
- Research Site — Boise, Idaho
- Research Site — Noblesville, Indiana
- Research Site — West Des Moines, Iowa
- Research Site — Hutchinson, Kansas
- Research Site — Kansas City, Kansas
- Research Site — Louisville, Kentucky
- Research Site — White Marsh, Maryland
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.